Ignite Creation Date:
2024-05-06 @ 7:27 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06016062
Status:
RECRUITING
Last Update Posted:
2023-11-29
First Post:
2023-08-18
Brief Title:
A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Sponsor:
RemeGen Co Ltd
Organization:
RemeGen Co Ltd
Study Overview
Official Title:
Safety Tolerability Pharmacokinetics and Efficacy of RC148 in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors an Open-Label Multicenter Phase I Trial
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is to evaluate the safety tolerability maximum tolerated dose MTD maximum administered dose MAD pharmacokinetics PK pharmacodynamics immunogenicity and recommended Phase 2 dose RP2D of RC148 in participants with locally advanced unresectable or metastatic solid tumorsIn addition the preliminary anti-tumour efficacy of RC148 as single agent will be assessed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None